Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl

Ocular Hypertension Clinical Trial

— NOPAPS  

Official title:

Safety and Efficacy Study in NTG, POAG, Glaucoma Suspect, Ocular Hypertension Patients With Diagnosed Prostaglandin Associated Peri-orbitopathy Switching From Preserved Prostaglandin Analogues Monotherapy to Omidenepag Isopropyl

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05279716
• Other study ID #: NO-PAPS-Study
• Status: Recruiting
• Phase: Phase 4
• Start date: February 15, 2022
• Est. completion date: November 20, 2023

Study information

• Verified date: February 2022
• Source: Santen Pharmaceutical Asia Pte. Ltd.
• Contact: UMT Director
• Phone: 010-3386-0603
• Email: csyu[@]e-umt.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is for patients have been using prostaglandin analogue eye drops with a preservative for 3 months or more and have been diagnosed with prostaglandin-associated peri-orbital disease.

the investigators would like to confirm the real world evidence(RWE) of safety and efficacy after changing to Eybelis ophthalmic solution 0.002%.

Description:

This clinical trial is a single-arm, multicenter, prospective clinical trial, in which participants have consented to participate in the clinical trial are sequentially registered and proceeded.

The participant's participation period is a total of 24 weeks after the 4-week wash-out period, and according to the visit schedule, tests according to medical procedures are conducted at Screening, Baseline, 6, 12, 18, and 24 weeks to collect data on safety and effectiveness.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: November 20, 2023
• Est. primary completion date: December 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 79 Years

Eligibility

Inclusion Criteria:

1. Adults between 19 and 79 years of age.

2. Normal Tension Glaucoma, Primary open-angle glaucoma, Glaucoma suspect and Ocular hypertension patients.

3. Patients who have received prostaglandin analogue (PGA) eye drops with preservatives for at least 3 months from the date of consent.

4. Patients diagnosed with prostaglandin associated peri-orbitopathy due to the use of Prostaglandin analogue (PGA) eye drops with preservatives.

• DUES (Deepening of Upper Eyelid Sulcus)

• FLEB (Flattening of Lower Eyelid Bag)

• Upper eyelid ptosis

• Periorbital hyperpigmentation

• Ciliary hypertrichosis

5. Those who have agreed in writing to participate in this clinical trial.

Exclusion Criteria:

1. Patients with glaucoma caused by secondary causes such as pseudo-exfoliative glaucoma and pigment dispersion syndrome

2. Patients with intraocular pressure greater than 34 mmHg

3. Patients with severe visual impairment (Mean deviation -20dB or more)

4. History of eye surgery within 6 months from the date of consent (Corneal refractive surgery or intraocular surgery including LASIK and LASEK that affect the condition of the ocular surface)

5. Patients with severe dry eyes (those receiving or in need of drug treatment), those with eye allergies, infections, or inflammatory diseases

6. Those who are using systemic or eye steroids (except for topical skin)

7. Those who are using eye drops for the treatment of glaucoma other than Prostaglandin analogues eye drops with preservatives

8. Pregnant or lactating women

9. Those with hypersensitivity to anesthetic eye drops, fluorescein, or research drugs

10. Those who need to wear contact lenses during the clinical trial period

11. Artificial lens eye (pseudophakia) or aphakic eye (aphakia)

12. Periocular trauma, surgical history, or thyroid orbitopathy affecting the evaluation of prostaglandin associated peri-orbitopathy

13. Other clinical investigators judged to be inappropriate to participate in clinical trials

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Open-Angle
• Glaucoma, Suspect
• Hypertension
• Low Tension Glaucoma
• Normal Tension Glaucoma
• Ocular Hypertension
• Primary Open-angle Glaucoma

Intervention

Drug:
• Eybelis ophthalmic solution 0.002%
Ophthalmic eye drop

Locations

Country	Name	City	State
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam-si
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Kangbuk Samsung Hospital	Seoul
Korea, Republic of	Kim's Eye Hospital	Seoul
Korea, Republic of	Korea University Anam Hospital	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Seoul ST. Mary's Hospital	Seoul
Korea, Republic of	Severance Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Santen Pharmaceutical Asia Pte. Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement rate of DUES(Deepening of Upper Eyelid Sulcus)	Primary efficacy parameter in prostaglandin associated peri-orbitopathy diseases at 24 weeks compared to baseline.; -DUES (Deepening of Upper Eyelid Sulcus) Evaluate based on the following criteria.; Grading is evaluated from 0 to 4 points. grade 0 = none; grade 1 = trace, barely visible; grade 2 = mild; grade 3 = moderate, easily detected; grade 4 = severe;	24 weeks
Secondary	Improvement rate of FLEB (Flattening of Lower Eyelid Bag)	second efficacy parameter in prostaglandin associated peri-orbitopathy diseases at 24 weeks compared to baseline.; Facial photos, including eyebrows and lower eyelids, are taken by the investigator with the same digital camera and without flash in the same room conditions.; When registering participants, the principal investigator of the conducting institution evaluates and registers participants, and the final evaluation is evaluated by three independent evaluators by randomly arranging the pictures taken during the visit so that the order of the visit is unknown.	24 weeks
Secondary	Improvement rate of Upper eyelid ptosis in prostaglandin-associated peri-orbitopathy	second efficacy parameter in prostaglandin associated peri-orbitopathy diseases at 24 weeks compared to baseline.; -Upper eyelid ptosis Margin reflex distance (MRD) is measured, and MRD 1 and MRD 2 are measured, respectively.; This is measured to evaluate the palpebral fissure height.; Grading is evaluated by the difference between the values of MRD 1 and MRD 2. mild = less than 2 mm; moderate = more than 2 mm and less than 4 mm; severe = more than 4 mm;	24 weeks
Secondary	Improvement rate of Periorbital hyperpigmentation in prostaglandin-associated peri-orbitopathy	second efficacy parameter in prostaglandin associated peri-orbitopathy diseases at 24 weeks compared to baseline.; -Periorbital hyperpigmentation Periorbital hyperpigmentation around the eyes is evaluated compared to the surrounding skin.; Grading is evaluated from 0 to 4 points. grade 0 = skin color comparable to other facial skin areas; grade 1 = faint pigmentation of infraorbital fold; grade 2 = pigmentation more pronounced; grade 3 = deep dark color, all four lids involved; grade 4 = grade 3+ pigmentation spreading beyond infraorbital fold;	24 weeks
Secondary	Improvement rate of Ciliary hypertrichosis in prostaglandin-associated peri-orbitopathy	second efficacy parameter in prostaglandin associated peri-orbitopathy diseases at 24 weeks compared to baseline.; Facial photos, including eyebrows and lower eyelids, are taken by the investigator with the same digital camera and without flash in the same room conditions.; When registering participants, the principal investigator of the conducting institution evaluates and registers participants, and the final evaluation is evaluated by three independent evaluators by randomly arranging the pictures taken during the visit so that the order of the visit is unknown.	24 weeks
Secondary	Changes in intraocular pressure (IOP)	second efficacy parameter in intraocular pressure at 24 weeks compared to baseline.	24 weeks
Secondary	Response rate of changes in intraocular pressure (IOP)	second efficacy parameter in Response rate of changes in intraocular pressure at 24 weeks compared to baseline.	24 weeks
Secondary	Expression rate, number and change of Conjunctival Hyperemia	- Conjunctival Hyperemia Conjunctival Hyperemia is performed according to the evaluation criteria of the Japanese Ocular Allergy Society (JOAS).; Grading is evaluated from 0 to 3 points. Grade 0 = No vasodilation; Grade 1= Some vessel vasodilation; Grade 2 = Excessive vessel vasodilation; Grade 3 = Overall vasodilation;	24 weeks
Secondary	Expression rate, number and change of Macular Edema	-Macular Edema; Inspect with Optical Coherence Tomography.; Clinically significant macular edema in the following cases evaluate.; Thickening of the retina at or within 500 µm of the center of the macula.; Hard exudates at or within 500 µm of the center of the macula that associated with thickening of adjacent retina (which may lie more than 500 µm from the center of the macula).; A zone or zones of retinal thickening 1 disc area or larger, any part of which is within 1 disc diameter of the center of the macula	24 weeks
Secondary	Expression rate, number and change of Cystoid Macular Edema	-Cystoid Macular Edema; Inspect with Optical Coherence Tomography. CME I = cysts less than 30% macular thickness; CME II = cysts between 30% and 60% of macular thickness; CME III = cysts between 60% and 90% of macular thickness; CME IV = cysts became more than 90% of the macular thickness;	24 weeks
Secondary	Expression rate, number and change of Endothelial Cell Count	-Endothelial Cell Count; Measure with a specular microscope and check CD (Cell Density, cells/mm^2), CV (Coefficient of Variation), HEX (Hexagonality, %), NUM (number excluding incorrect count cells when counting cells) do.	24 weeks
Secondary	Expression rate, number and change of Central Corneal Thickness	-Central Cornea Thickness; After eye drop anesthesia, it is measured with an Ultrasonic Pachymeter(µm).	24 weeks